Esperion Therapeutics (NASDAQ:ESPR) Price Target Cut to $3.00 by Analysts at The Goldman Sachs Group

Esperion Therapeutics (NASDAQ:ESPR) had its price objective cut by The Goldman Sachs Group from $4.00 to $3.00 in a research report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on ESPR. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Esperion Therapeutics in a report on Tuesday, April 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.42.

Esperion Therapeutics Stock Down 1.4 %

Shares of Esperion Therapeutics stock opened at $0.95 on Thursday. Esperion Therapeutics has a 52-week low of $0.93 and a 52-week high of $3.94. The company has a market capitalization of $187.96 million, a P/E ratio of -1.48 and a beta of 0.86. The company has a 50 day moving average of $1.51 and a 200 day moving average of $2.00.

Hedge Funds Weigh In On Esperion Therapeutics

Several large investors have recently bought and sold shares of ESPR. State Street Corp lifted its holdings in shares of Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the last quarter. Wellington Management Group LLP increased its position in Esperion Therapeutics by 66.8% during the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock worth $995,000 after buying an additional 241,512 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics in the third quarter valued at approximately $606,000. Barclays PLC boosted its holdings in shares of Esperion Therapeutics by 99.6% in the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 154,509 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.